AC Immune SA (ACIU)
2.39
-0.05
(-2.05%)
USD |
NASDAQ |
May 03, 16:00
2.39
0.00 (0.00%)
After-Hours: 20:00
AC Immune Revenue (Quarterly): 16.70M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.70M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 0.001M |
| September 30, 2022 | 4.073M |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 1.044M |
| September 30, 2020 | 1.221M |
| June 30, 2020 | 1.124M |
| March 31, 2020 | 12.69M |
| December 31, 2019 | 0.8688M |
| September 30, 2019 | 33.70M |
| Date | Value |
|---|---|
| June 30, 2019 | 1.507M |
| March 31, 2019 | 75.31M |
| December 31, 2018 | 1.126M |
| September 30, 2018 | 2.343M |
| June 30, 2018 | 2.059M |
| March 31, 2018 | 1.537M |
| December 31, 2017 | 16.63M |
| September 30, 2017 | 1.116M |
| June 30, 2017 | 0.7643M |
| March 31, 2017 | 1.997M |
| December 31, 2016 | 1.429M |
| September 30, 2016 | 1.366M |
| June 30, 2016 | 20.56M |
| March 31, 2016 | 0.4902M |
| December 31, 2015 | 0.3178M |
| September 30, 2015 | 25.26M |
| June 30, 2015 | 15.03M |
| March 31, 2015 | 0.2468M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.001M
Minimum
Dec 2022
33.70M
Maximum
Sep 2019
7.294M
Average
1.364M
Median
Revenue (Quarterly) Benchmarks
| CRISPR Therapeutics AG | 200.00M |
| Addex Therapeutics Ltd | 0.1731M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 1.164M |
| MoonLake Immunotherapeutics | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.353M |
| Total Expenses (Quarterly) | 20.70M |
| EPS Diluted (Quarterly) | -0.0564 |
| Enterprise Value | 113.68M |
| Profit Margin (Quarterly) | -32.05% |
| Earnings Yield | -29.69% |
| Normalized Earnings Yield | -29.69 |